PanTarg
PanTarg develops antibody-drug conjugates for pancreatic cancer and other solid tumors.
Pre Seed ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredFeb 1, 2024 (2 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Pre Seed | undisclosed | — | — |
Timeline
- Website created
Founders and team
- LHLars H. Engelholm CEO and co-foundersource: pantarg.com
VM
Virginia Metrangolo CSO and co-foundersource: pantarg.com
Investors
Companies like PanTarg
PPhrontline Biopharma$40M Series A · Nov 2026
OOna Therapeutics$86.6M Series B+ · Oct 2026
AAdcendo$75M Series B+ · Apr 2026
TTubulis$360M Series B+ · Oct 2025VVelosbioSeries B+ · Aug 2026
AAbTx$1.95M Seed · Sep 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/pantarg (get a free API key).